Drugs /

muc1 peptide-poly-iclc vaccine

Back to Drugs List

Overview

NCI Definition [1]:
A vaccine preparation containing mucus 1 (MUC1) peptide and the adjuvant poly-ICLC with potential immunostimulatory and antineoplastic activities. Upon administration, MUC1 peptide-poly-ICLC adjuvant vaccine may induce the host immune system to mount a cytotoxic T cell response against MUC1-expressing tumor cells. MUC1, a tumor associated antigen normally present on the lining of the human colon, may be overexpressed and/or mutated in a variety of cancer cell types. The adjuvant poly-ICLC, a ligand for toll-like receptor-3, induces the release of cytokines which may help boost the immune response against MUC1.

Clinical Trials

View Clinical Trials for muc1 peptide-poly-iclc vaccine

Muc1 peptide-poly-iclc vaccine has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating muc1 peptide-poly-iclc vaccine, 1 is phase 1/phase 2 (1 open).

Non-small cell lung carcinoma is the most common disease being investigated in muc1 peptide-poly-iclc vaccine clinical trials [2].

Drug Details

NCIT ID [1]:
C82417

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.